HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Lepromin

Networked: 229 relevant articles (5 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Goulart, Isabela Maria Bernardes: 4 articles (12/2015 - 12/2004)
2. Goulart, Luiz Ricardo: 3 articles (12/2015 - 12/2004)
3. Sharma, P: 3 articles (06/2000 - 06/2000)
4. Kaur, H: 3 articles (06/2000 - 06/2000)
5. Kar, H K: 3 articles (06/2000 - 06/2000)
6. Rani, R: 3 articles (06/2000 - 06/2000)
7. Mukherjee, R: 3 articles (06/2000 - 06/2000)
8. Misra, R S: 3 articles (06/2000 - 06/2000)
9. Mukherjee, A: 3 articles (06/2000 - 06/2000)
10. Ferreira, Frederico Rogério: 2 articles (10/2006 - 12/2004)

Related Diseases

1. Leprosy (Hansen's Disease)
01/01/1966 - "The conclusion is reached that the anergic, or factor N, hypothesis that has been evolved to relate the lepromin test to the findings in clinical leprosy appears to be the most promising, and that, if this hypothesis can be substantiated, it is unlikely that BCG vaccination can be a very useful tool for prevention. "
07/01/1975 - "With the significant information compiled in this study, it is concluded that lepromin prepared from bacilli obtained from infected armadillos is as effective as that prepared from bacilli obtained from the lesions of leprosy patients."
09/01/1999 - "The lepromin response evaluated in terms of percentage of subjects converting to positivity status, measurement in millimeters, and duration of lepromin positivity sustained, reflected a statistically significant better outcome in the vaccine group patients (especially LL and BL leprosy) in comparison to those in the placebo group. "
07/01/1996 - "The findings in the study showed specific unresponsiveness to lepromin in LMI in leprosy contacts of less than two years duration, direct contacts, contacts of lepromatous spectrum of index patients and contacts not vaccinated with B.C.G. "
03/01/1994 - "In this study, we measured in vitro proliferative responses of peripheral blood mononuclear cells from both leprosy patients across the clinical spectrum and also healthy contacts from a leprosy-endemic population to delipidified cell components of Mycobacterium leprae (DCC) and Dharmendra lepromin. "
2. Lepromatous Leprosy
3. Hypersensitivity (Allergy)
4. Asymptomatic Infections
5. Infection

Related Drugs and Biologics

1. Dapsone
2. BCG Vaccine
3. Tuberculin (PPD)
4. Antigens
5. anti-leprosy vaccine
6. Antibodies
7. Immunoglobulin M (IgM)
8. Dinitrochlorobenzene (DNCB)
9. Levamisole (Decaris)
10. Immunoglobulin G (IgG)

Related Therapies and Procedures

1. Chemoprevention
2. Immunotherapy
3. Drug Therapy (Chemotherapy)
4. Injections
5. Immunomodulation